A mong the 100 million adults worldwide ≥45 years of age who undergo major noncardiac surgery annually, it is estimated that 3 million will suffer a perioperative myocardial infarction (MI).
associated with an increased risk of 30-day mortality (adjusted hazard ratio [HR], 3.20; 95% CI, 2.37-4.32). 6 In POISE, perioperative MI was also associated with a 6-and 8-fold increase in the risk of nonfatal cardiac arrest and congestive heart failure, respectively, at 30 days. 2 VISION demonstrated similar findings for MINS. 6 A recent Swiss study of 2018 consecutive patients ≥65 years or 45 to <65 years of age with known vascular disease who underwent major noncardiac surgery and systematic perioperative troponin screening demonstrated that MINS was independently associated with an increased risk of mortality at 1 year (adjusted HR, 1.48; 95% CI, 1.07-2.06). 7 A systematic review identified 5 studies that systematically screened troponin measurements after noncardiac surgery and followed patients beyond 30 days. 8 All studies demonstrated that an elevated troponin measurement after surgery was independently associated with an increased risk of major cardiovascular events in the subsequent 6 to 18 months.
In this issue of Circulation, Smilowitz and colleagues 9 provide important new insights into the prognosis of perioperative MI. Using a large administrative database, they identified 8085 patients who had an MI after noncardiac surgery in 2014. Among patients diagnosed with a perioperative MI compared with patients not diagnosed with a perioperative MI, during the index hospitalization the absolute incidence of mortality was 13% higher, the length of stay was 6 days longer, and the absolute cost of care was $17 000 more (P<0.001 for all comparisons). Among survivors of the index hospitalization who had a perioperative MI, at 30-day follow-up (1) there was a 19% incidence of hospital readmission; (2) the readmission happened a median of 2 weeks after the MI; (3) a cardiovascular complication was the indication for hospital readmission in 25% of patients, and an additional 16% of patients had an acute cardiovascular complication, although it was not the primary indication for readmission; (4) 11% died during the readmission; and (5) the readmission cost a median of ≈$9900. Perioperative MI was an independent predictor of readmission (adjusted OR, 1.39; 95% CI, 1.31-1.48). Approximately half of the patients were followed for 6 months, and among the patients who had a perioperative MI during their index hospital admission, 15% died and 42% were readmitted to the hospital. These data highlight the substantial risk of mortality, recurrent cardiovascular complications, readmission, and costs associated with perioperative MI.
MANAGEMENT
Despite the poor prognosis of patients with perioperative MI or MINS, research suggests that a substantial proportion of these patients do not receive secondary prophylactic cardiovascular interventions. In POISE, among the 415 patients who had a perioperative MI, at hospital discharge, 35% of these patients were not receiving aspirin, 48% were not receiving a statin, and 45% were not receiving an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker. 2 In a study from The Netherlands with routine troponin measurements after noncardiac surgery, 715 patients had myocardial injury, and at baseline, 37%, 38%, 41%, and 42% of these patients were receiving aspirin, a β-blocker, an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, or a statin, respectively. 10 Medical management was only recorded in the 270 patients (41%) who had a cardiology consult. Although a minority of patients with myocardial injury were receiving cardiovascular medications, cardiology only recommended a β-blocker in 18%, aspirin in 12%, another antiplatelet agent in 5%, a statin in 8%, and an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker in <7% of patients.
THERAPEUTIC EVIDENCE
Multivariable analyses that assessed the relationship between cardiovascular drugs and 30-day mortality in patients who had a perioperative MI in POISE suggested a benefit of aspirin (adjusted OR, 0.54; 95% CI, 0.29-0.99) and statin therapy (adjusted OR, 0.26; 95% CI, 0.13-0.54).
2 A case-control study from France evaluated 66 patients who had MINS and 132 matched patients who had vascular surgery without MINS. 11 Among the patients with MINS, 65% received cardiovascular medication intensification (ie, the addition or increased dose of ≥1 of the following medications: antiplatelet agent, statin, β-blocker, and angiotensin-converting enzyme inhibitor). The primary outcome was death, MI, coronary revascularization, or pulmonary edema requiring hospitalization at 1 year. Patients with MINS without cardiovascular medication intensification had an HR of 1.77 (95% CI, 1.13-2.42) for the primary outcome compared with the matched non-MINS control group. In contrast, patients with MINS who received cardiovascular medication intensification had an HR of 0.63 (95% CI, 0.10-1.19) compared with the matched non-MINS control group. Patients with MINS without compared to patients with MINS with cardiovascular medication intensification had an HR of 2.80 (95% CI, 1.05-24.20) for the primary outcome. The CRIPES trial (Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery) demonstrated complementary evidence in that patients with myocardial injury after vascular surgery who received cardiovascular medication intensification had a 8% readmission rate at 6 months compared with a 25% readmission rate in patients without cardiovascular medication intensification (P=0.02). 12 The only randomized controlled trial to evaluate an intervention among patients with MINS is the MAN-AGE trial (Management of Myocardial Injury After Noncardiac Surgery), 13 and the results were reported at the 2018 Late-Breaking Trial Session of the American College of Cardiology. MANAGE randomized 1754 patients with MINS to dabigatran 110 mg twice daily (877 patients) or placebo (877 patients), and patients took the intervention and were followed for a mean of 16 months. The primary efficacy outcome (ie, a composite of vascular mortality and nonfatal MI, nonhemorrhagic stroke, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolism) occurred in 11% of patients randomized to dabigatran and 15% of patients randomized to placebo (P=0.011). Although dabigatran increased the risk of minor bleeding (HR, 1.64; 95% CI, 1.25-2.15), it did not increase the risk of the composite of life-threatening, major, or critical organ bleeding (HR, 0.92; 95% CI, 0.55-1.53).
WHAT PHYSICIANS SHOULD DO
There is strong evidence demonstrating a substantial increased risk of mortality and major cardiovascular complications in patients who have a perioperative MI or isolated ischemic troponin elevation. 2, [5] [6] [7] 10 Although the majority of these events are asymptomatic, they carry a poor prognosis. This finding highlights the need for perioperative troponin measurements in at-risk patients to ensure that prognostically important asymptomatic MIs and isolated ischemic troponin elevations are not missed, along with the potential for risk modification. Recently, the Canadian Cardiovascular Society Guidelines on perioperative cardiac risk assessment and management gave a strong recommendation for obtaining daily troponin measurements for 48 to 72 hours after noncardiac surgery in patients with a baseline risk >5% for cardiovascular death or nonfatal MI at 30 days after surgery (eg, patients 45-64 years of age with significant cardiovascular disease or ≥65 years of age). 14 Given the direct perioperative risk-adjusted observational data and the indirect secondary prophylaxis clinical trial data, patients with MINS should receive a statin and aspirin if there is no evidence of bleeding. Based on the MANAGE results, patients who have access to dabigatran 110 mg twice daily should be considered for this intervention. These patients also require follow-up to maintain long-term cardiovascular health.
SUMMARY
Perioperative MI and MINS are common and associated with suboptimal outcomes. A minority of patients who have these events are identified because of the lack of routine perioperative troponin measurements, receive secondary prophylactic interventions, or are seen or followed by a cardiologist or cardiovascular specialist. The cardiovascular community could help this high-risk patient population through obtaining perioperative troponin measurements in at-risk patients, initiating a statin and aspirin and dabigatran 110 mg twice daily in patients with MINS who are not bleeding, and following these patients after hospital discharge to ensure optimal transition of care and long-term cardiovascular health. 
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